Yahoo Finance

Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 ...

KANSAS CITY, Kan., May 20, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...
Seeking Alpha

Cingulate completes Phase 3 adult study for ADHD drug candidate

Cingulate (NASDAQ:CING) said it has completed a Phase 3 study for its drug candidate CTx-1301 in the treatment of ADHD in adults and has slated the initiation of a pivotal Phase 3 pediatric study to ...
MSN による配信

Cingulate Retail Buzz Surges As ADHD Drug Shows Phase 3 Pediatric Efficacy

Retail chatter around Cingulate spiked Tuesday after Phase 3 data confirmed that its lead candidate, CTx-1301, significantly improved ADHD symptoms in pediatric patients within five weeks of treatment ...
Seeking Alpha

FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD ...

KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (CING) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform ...